Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ZFGN
CUSIPN/A
Phone617-622-4003
Debt
Debt-to-Equity Ratio0.36
Current Ratio8.42
Quick Ratio8.42
Price-To-Earnings
Trailing P/E Ratio-5.44
Forward P/E Ratio-5.04
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.85 per share
Price / Book3.63
Profitability
EPS (Most Recent Fiscal Year)($1.90)
Net Income$-52,020,000.00
Net MarginsN/A
Return on Equity-80.72%
Return on Assets-61.36%
Miscellaneous
Employees35
Outstanding Shares36,810,000
Market Cap$382.04 million
Zafgen (NASDAQ:ZFGN) Frequently Asked Questions
What is Zafgen's stock symbol?
Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."
How were Zafgen's earnings last quarter?
Zafgen Inc (NASDAQ:ZFGN) issued its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.59) by $0.02. View Zafgen's Earnings History.
When is Zafgen's next earnings date?
What price target have analysts set for ZFGN?
4 brokers have issued 12-month price targets for Zafgen's shares. Their forecasts range from $14.00 to $20.00. On average, they anticipate Zafgen's stock price to reach $17.3333 in the next twelve months. This suggests a possible upside of 67.6% from the stock's current price. View Analyst Price Targets for Zafgen.
What is the consensus analysts' recommendation for Zafgen?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zafgen.
Are investors shorting Zafgen?
Zafgen saw a increase in short interest during the month of September. As of September 14th, there was short interest totalling 1,166,230 shares, an increase of 37.9% from the August 31st total of 845,684 shares. Based on an average daily trading volume, of 246,569 shares, the days-to-cover ratio is currently 4.7 days. Currently, 3.5% of the company's stock are short sold. View Zafgen's Current Options Chain.
Who are some of Zafgen's key competitors?
Some companies that are related to Zafgen include ARMO Biosciences (ARMO), Zogenix (ZGNX), Portola Pharmaceuticals (PTLA), Myovant Sciences (MYOV), Corcept Therapeutics (CORT), Biohaven Pharmaceutical (BHVN), Spectrum Pharmaceuticals (SPPI), Wave Life Sciences (WVE), Clovis Oncology (CLVS), Impax Laboratories (IPXL), Mirati Therapeutics (MRTX), IMMURON Ltd/S (IMRN), TherapeuticsMD (TXMD), Tricida (TCDA) and Insmed (INSM).
Who are Zafgen's key executives?
Zafgen's management team includes the folowing people:
- Mr. Jeffrey S. Hatfield, CEO & Director (Age 60)
- Dr. Thomas E. Hughes, Pres & Chief Scientific Officer (Age 58)
- Ms. Patricia L. Allen, Chief Financial Officer (Age 56)
- Dr. Dennis D. Kim M.D., MBA, Chief Medical Officer (Age 48)
- Dr. James E. Vath Ph.D., Head of Discovery and Devel. (Age 57)
How do I buy shares of Zafgen?
Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zafgen's stock price today?
One share of ZFGN stock can currently be purchased for approximately $10.34.
How big of a company is Zafgen?
Zafgen has a market capitalization of $382.04 million. The biopharmaceutical company earns $-52,020,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Zafgen employs 35 workers across the globe.
What is Zafgen's official website?
How can I contact Zafgen?
Zafgen's mailing address is 175 PORTLAND STREET 4TH FLOOR, BOSTON MA, 02114. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]
MarketBeat Community Rating for Zafgen (NASDAQ ZFGN)
MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote "Outperform" if you believe ZFGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZFGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
